26
Jun
Danish pharmaceutical giant Novo Nordisk has launched Wegovy®, a once-weekly injectable medication for chronic weight management, in India. Uniquely, Wegovy® is the first and only treatment in the country approved not only for weight loss but also for reducing major cardiovascular risks, including heart attack, stroke, and cardiovascular-related death in individuals with obesity or overweight. Wegovy®, containing the active ingredient Semaglutide, is available in five dosing strengths and comes in an easy-to-use pen device. The India-specific pricing includes the same cost for the first three doses, supporting smooth dosage escalation without additional financial burden. Clinical studies have shown that 1…
